Update on Parkinson Disease

Annals of Internal Medicine

Volumn 138, Issue 8, 2003, Pages 651-658

  Siderowf, Andrew ^a   Stern, Matthew ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE; ALPHA SYNUCLEIN; BROMOCRIPTINE; CAFFEINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; FLUORINE 18; IODINE 123; LEVODOPA; PARKIN; PESTICIDE; PRAMIPEXOLE; ROPINIROLE; ROTENONE; TYROSINE 3 MONOOXYGENASE; ANTIPARKINSON AGENT;

BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; CLINICAL TRIAL; DYSKINESIA; EDEMA; ENVIRONMENTAL FACTOR; FETUS CELL; GENE MUTATION; GLOBUS PALLIDUS; HALLUCINATION; HEREDITY; HUMAN; NEUROPROTECTION; NONHUMAN; PALLIDOTOMY; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE; SUBTHALAMIC NUCLEUS; THALAMOTOMY; ENVIRONMENT; FETAL TISSUE TRANSPLANTATION; GENETICS;

ANTIPARKINSON AGENTS; CELL TRANSPLANTATION; DOPAMINE AGONISTS; ENVIRONMENT; FETAL TISSUE TRANSPLANTATION; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 0037501731     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-138-8-200304150-00013     Document Type: Review

References (52)

1. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin. 1996;14:317-35. [PMID: 8827174]
2. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J Med. 1969;280:337-45. [PMID: 4178641]
3. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-80. [PMID: 6823561]
4. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. Parkinson disease in twins: an etiologic study. JAMA. 1999;281:341-6. [PMID: 9929087]
5. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology. 1983;33:815-24. [PMID: 6683366]
6. Vieregge P, Schiffke KA, Friedrich HJ, Müller B, Ludin HP. Parkinson's disease in twins. Neurology. 1992;42:1453-61. [PMID: 1641135]
7. Marttila RJ, Kaprio J, Koskenvuo M, Rinne UK. Parkinson's disease in a nationwide twin cohort. Neurology. 1988;38:1217-9. [PMID: 3399070]
8. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999;45:577-82. [PMID: 10319879]
9. Sveinbjörnsdottir S, Hicks AA, Jonsson T, Pétursson H, Guǧmundsson G, Frigge ML, et al. Familial aggregation of Parkinson's disease in Iceland. N Engl J Med. 2000;343:1765-70. [PMID: 11114315]
10. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605-8. [PMID: 9560156]
11. Lücking CB, Dürr A, Bonifati V, Vaughan J, De Michele G, Gasser T, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group, N Engl J Med. 2000;342:1560-7. [PMID: 10824074]
12. Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001;286:2239-44. [PMID: 11710888]
13. Farrer M, Gwinn-Hardy K, Muenter M, DeVrieze FW, Crook R, Perez-Tur J, et al. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet. 1999;8:81-5. [PMID: 9887334]
14. Gasser T, Müller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet. 1998;18:262-5. [PMID: 9500549]
15. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology. 2000;55:533-8. [PMID: 10953187]
16. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045-7. [PMID: 9197268]
17. Scott WK, Yamaoka LH, Stajich JM, Scott BL, Vance JM, Roses AD, et al. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease [Letter]. Neurogenetics. 1999;2:191-2. [PMID: 10541595]
18. Vaughan JR, Farrer MJ, Wszolek ZK, Gasser T, Durr A, Agid Y, et al. Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD). Hum Mol Genet. 1998;7:751-3. [PMID: 9499430]
19. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988;8:2804-15. [PMID: 3411354]
20. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Nad Acad Sci U S A. 1998;95:6469-73. [PMID: 9600990]
21. Arawaka S, Saito Y, Murayama S, Mori H. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology. 1998;51:887-9. [PMID: 9748051]
22. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000;287:1265-9. [PMID: 10678833]
23. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature. 2000;404:394-8. [PMID: 10746727]
24. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25:302-5. [PMID: 10888878]
25. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A. 2000;97:13354-9. [PMID: 11078524]
26. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med. 2001;7:1144-50. [PMID: 11590439]
27. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology. 1992;42:733-8. [PMID: 1314341]
28. Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis. 2000;7:240-50. [PMID: 10964596]
29. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256-9. [PMID: 12446870]
30. Ciechanover A. Linking ubiquitin, parkin and synphilin-1. Nat Med. 2001;7:1108-9. [PMID: 11590431]
31. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinson's disease [Letter]. Nature. 1998;395:451-2. [PMID: 9774100]
32. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology. 1995;45:1041-51. [PMID: 7783862]
33. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283:2674-9. [PMID: 10819950]
34. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000;3:1301-6. [PMID: 11100151]
35. Fahn S. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology. 1974;24:431-41. [PMID: 4857104]
36. Fahn S. Is levodopa toxic? Neurology. 1996;47:S184-95. [PMID: 8959987]
37. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000;342:1484-91. [PMID: 10816186]
38. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA. 2000;284:1931-8. [PMID: 11035889]
39. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord. 1998;13:234-41. [PMID: 9539335]
40. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J Neurol Neurosurg Psychiatry. 1994;57:1034-8. [PMID: 8089666]
41. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653-61. [PMID: 11926889]
42. Whone AL, Remy P, Davis MR, et al. The REAL-PET study: slower progression in early Parkinson disease treated with ropinirole compared with l-dopa. Neurology. 2002;58(Suppl3):A82-3.
43. Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet. 2002;360:1767-9. [PMID: 12480442]
44. Marsden CD, Obeso JA. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain. 1994;117(Pt 4):877-97. [PMID: 7922472]
45. Fine J, Duff J, Chen R, Chir B, Hutchison W, Lozano AM, et al. Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. N Engl J Med. 2000;342:1708-14. [PMID: 10841873]
46. Baron MS, Vitek JL, Bakay RA, Green J, Kaneoke Y, Hashimoto T, et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol. 1996;40:355-66. [PMID: 8797525]
47. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 1998;339:1105-11. [PMID: 9770557]
48. Kumar R, Lozano AM, Kim YJ, Hutchison WD, Sime E, Halket E, et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology. 1998;51:850-5. [PMID: 9748038]
49. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med. 2001;345:956-63. [PMID: 11575287]
50. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001;344:710-9. [PMID: 11236774]
51. Macklin R. The ethical problems with sham surgery in clinical research. N Engl J Med. 1999;341:992-6. [PMID: 10498498]
52. Freeman TB, Vawter DE, Leaverton PE, Godbold JH, Hauser RA, Goetz CG, et al. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med. 1999;341:988-92. [PMID: 10498497]